Associated Papers
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F et al.
Neurobiology of Disease, 2021
Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes.
Boecker CA et al.
Current Biology : Cb, 2021
GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
Thomas JM et al.
Journal of Cellular Physiology, 2020
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation.
Bae EJ et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2020
LRRK2 Phosphorylation, More Than an Epiphenomenon.
Marchand A et al.
Frontiers in Neuroscience, 2020
LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models.
Dues DJ et al.
Frontiers in Neuroscience, 2020
Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.
Shani V et al.
Human Molecular Genetics, 2019
LRRK2 enhances Nod1/2-mediated inflammatory cytokine production by promoting Rip2 phosphorylation.
Yan R et al.
Protein & Cell, 2017
Models of LRRK2-Associated Parkinson's Disease.
Xiong Y et al.
Advances in Neurobiology, 2017
LRRK2 Promotes Tau Accumulation, Aggregation and Release.
Guerreiro PS et al.
Molecular Neurobiology, 2016
Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
Shu Y et al.
Plos One, 2016
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E et al.
Neurobiology of Disease, 2015
Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T et al.
Human Molecular Genetics, 2014
Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.
Cho HJ et al.
The Embo Journal, 2014
A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Dusonchet J et al.
Human Molecular Genetics, 2014
Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Ito G et al.
Plos One, 2014
GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A et al.
Human Molecular Genetics, 2013
Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E et al.
Biochemical Society Transactions, 2012
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.
Pungaliya PP et al.
Plos One, 2010
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
Bmb Reports, 2010
Kinase activity of mutant LRRK2 mediates neuronal toxicity.
Smith WW et al.
Nature Neuroscience, 2006